Cholula maker McCormick forecasts tepid annual sales, profit
FILE PHOTO: McCormick & Company spices are seen on display in a store in Manhattan, New York City, U.S., March 29, 2022. REUTERS/Andrew Kelly/File Photo
(Refiles to add dropped word "low" in first paragraph. The story was earlier corrected to remove reference to "slowing demand, rising expenses" in headline and "persistent weakness" in paragraph 1. The error appeared in an earlier version of the story as well)
(Reuters) -Cholula hot sauce maker McCormick forecast annual sales and profit below analysts' estimates on Thursday, hurt by flat-to-low demand for its spices and condiments, especially in China, as well as higher marketing expenses.
Packaged food companies including McCormick, General Mills and Conagra Brands have also faced slowing demand across geographies as sticky inflation has compelled budget-conscious customers to hunt for value even for essential items such as groceries.
"The environment in China remains challenging," McCormick CEO Brendan Foley said on a post-earnings call, but he expects to see gradual recovery in the region through the year.
Foley also added McCormick was working towards making changes to product formulations including removal of artificial colors and sodium reduction after the U.S. Food and Drug Administration banned the use of a synthetic food dye that has shown to cause cancer in laboratory rats.
"These are areas that we have been working on, well up and prior to 2025," Foley said.
For fiscal year 2025, the company expects sales to be flat or grow as much as 2%, compared with analysts' estimate of a 2.4% rise, according to data compiled by LSEG. Sales had risen 0.9% in fiscal 2024 and 4.9% in 2023.
McCormick now projects annual adjusted profit to grow 3% to 5%, below expectations of 6.5%, according to data compiled by LSEG after posting a 2% rise in selling and general expenses in the fourth quarter.
Shares of the company, however, rose 2% after it reported a narrow beat for sales and profit in the fourth quarter ended Nov. 30.
The company posted net sales of $1.8 billion for the quarter, beating estimates of $1.77 billion, while it earned adjusted profit of 80 cent per share compared with analysts' estimates of 77 cents.
(Reporting by Neil J Kanatt in Bengaluru; Editing by Krishna Chandra Eluri)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox reports Q4 earnings beat on World Cup ad revenue boost, shares gain
- Lifetime Brands (LCUT) Tops Q2 EPS by 140c ; Offers Guidance
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
General News, ReutersRelated Entities
Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share